References
- Elhai M, Meune C, Avouac J, Kahan A, Allanore Y. Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies. Rheumatology (Oxford) 2012;51:1017-26. https://doi.org/10.1093/rheumatology/ker269
- Pokeerbux MR, Giovannelli J, Dauchet L, Mouthon L, Agard C, Lega JC, et al. Survival and prognosis factors in systemic sclerosis: data of a French multicenter cohort, systematic review, and meta-analysis of the literature. Arthritis Res Ther 2019;21:86. https://doi.org/10.1186/s13075-019-1867-1
- Barnes J, Mayes MD. Epidemiology of systemic sclerosis: incidence, prevalence, survival, risk factors, malignancy, and environmental triggers. Curr Opin Rheumatol 2012;24:165-70. https://doi.org/10.1097/BOR.0b013e32834ff2e8
- Cappelli S, Bellando Randone S, Camiciottoli G, De Paulis A, Guiducci S, Matucci-Cerinic M. Interstitial lung disease in systemic sclerosis: where do we stand? Eur Respir Rev 2015;24:411-9. https://doi.org/10.1183/16000617.00002915
- Bauer PR, Schiavo DN, Osborn TG, Levin DL, St Sauver J, Hanson AC, et al. Influence of interstitial lung disease on outcome in systemic sclerosis: a population-based historical cohort study. Chest 2013;144:571-7. https://doi.org/10.1378/chest.12-2768
- Walker UA, Tyndall A, Czirjak L, Denton C, Farge-Bancel D, Kowal-Bielecka O, et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. Ann Rheum Dis 2007;66:754-63. https://doi.org/10.1136/ard.2006.062901
- Wu W, Jordan S, Becker MO, Dobrota R, Maurer B, Fretheim H, et al. Prediction of progression of interstitial lung disease in patients with systemic sclerosis: the SPAR model. Ann Rheum Dis 2018;77:1326-32. https://doi.org/10.1136/annrheumdis-2018-213201
- Wangkaew S, Euathrongchit J, Wattanawittawas P, Kasitanon N, Louthrenoo W. Incidence and predictors of interstitial lung disease (ILD) in Thai patients with early systemic sclerosis: Inception cohort study. Mod Rheumatol 2016;26:588-93. https://doi.org/10.3109/14397595.2015.1115455
- Jung E, Suh CH, Kim HA, Jung JY. Clinical characteristics of systemic sclerosis with interstitial lung disease. Arch Rheumatol 2018;33:322-7. https://doi.org/10.5606/ArchRheumatol.2018.6630
- Bergamasco A, Hartmann N, Wallace L, Verpillat P. Epidemiology of systemic sclerosis and systemic sclerosis-associated interstitial lung disease. Clin Epidemiol 2019;11:257-73. https://doi.org/10.2147/CLEP.S191418
- Unhapipatpong C, Mahakkanukrauh A, Foocharoen C, Suwannaroj S, Nanagara R, Tumsatan P. Pulmonary manifestation in systemic sclerosis in Srinagarind Hospital. J Med Assoc Thai 2018;101:213.
- Degano B, Soumagne T, Eberst G, Meaux-Ruault N, Gil H, Magy-Bertrand N. Pulmonary function parameters other than vital capacity should be considered in screening for interstitial lung disease in patients with systemic sclerosis: comment on the article by Suliman et al. Arthritis Rheumatol 2016;68:2346-7. https://doi.org/10.1002/art.39778
- van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum 2013;65:2737-47. https://doi.org/10.1002/art.38098
- Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980;23:581-90. https://doi.org/10.1002/art.1780230510
- McNearney TA, Reveille JD, Fischbach M, Friedman AW, Lisse JR, Goel N, et al. Pulmonary involvement in systemic sclerosis: associations with genetic, serologic, sociodemographic, and behavioral factors. Arthritis Rheum 2007;57:318-26. https://doi.org/10.1002/art.22532
- Markusse IM, Meijs J, de Boer B, Bakker JA, Schippers HP, Schouffoer AA, et al. Predicting cardiopulmonary involvement in patients with systemic sclerosis: complementary value of nailfold videocapillaroscopy patterns and disease-specific autoantibodies. Rheumatology (Oxford) 2017;56:1081-8.
- Le Gouellec N, Duhamel A, Perez T, Hachulla AL, Sobanski V, Faivre JB, et al. Predictors of lung function test severity and outcome in systemic sclerosis-associated interstitial lung disease. PLoS One 2017;12:e0181692. https://doi.org/10.1371/journal.pone.0181692
- Liaskos C, Marou E, Simopoulou T, Barmakoudi M, Efthymiou G, Scheper T, et al. Disease-related autoantibody profile in patients with systemic sclerosis. Autoimmunity 2017;50:414-21. https://doi.org/10.1080/08916934.2017.1357699
- Graf SW, Hakendorf P, Lester S, Patterson K, Walker JG, Smith MD, et al. South Australian Scleroderma Register: autoantibodies as predictive biomarkers of phenotype and outcome. Int J Rheum Dis 2012;15:102-9. https://doi.org/10.1111/j.1756-185X.2011.01688.x
- Pandey AK, Wilcox P, Mayo JR, Sin D, Moss R, Ellis J, et al. Predictors of pulmonary hypertension on high-resolution computed tomography of the chest in systemic sclerosis: a retrospective analysis. Can Assoc Radiol J 2010;61:291-6. https://doi.org/10.1016/j.carj.2010.02.006
- Ryerson CJ, O'Connor D, Dunne JV, Schooley F, Hague CJ, Murphy D, et al. Predicting mortality in systemic sclerosisassociated interstitial lung disease using risk prediction models derived from idiopathic pulmonary fibrosis. Chest 2015;148:1268-75. https://doi.org/10.1378/chest.15-0003
- Moore OA, Proudman SM, Goh N, Corte TJ, Rouse H, Hennessy O, et al. Quantifying change in pulmonary function as a prognostic marker in systemic sclerosis-related interstitial lung disease. Clin Exp Rheumatol 2015;33(4 Suppl 91):S111-6.
- Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011;183:788-824. https://doi.org/10.1164/rccm.2009-040GL
- Zappala CJ, Latsi PI, Nicholson AG, Colby TV, Cramer D, Renzoni EA, et al. Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis. Eur Respir J 2010;35:830-6. https://doi.org/10.1183/09031936.00155108
- Gilson M, Zerkak D, Wipff J, Dusser D, Dinh-Xuan AT, Abitbol V, et al. Prognostic factors for lung function in systemic sclerosis: prospective study of 105 cases. Eur Respir J 2010;35:112-7. https://doi.org/10.1183/09031936.00060209
- Wells AU, Behr J, Silver R. Outcome measures in the lung. Rheumatology (Oxford) 2008;47 Suppl 5:v48-50. https://doi.org/10.1093/rheumatology/ken311
- Khanna D, Seibold JR, Wells A, Distler O, Allanore Y, Denton C, et al. Systemic sclerosis-associated interstitial lung disease: lessons from clinical trials, outcome measures, and future study design. Curr Rheumatol Rev 2010;6:138-44. https://doi.org/10.2174/157339710791330768
- Guilherme RF, Xisto DG, Kunkel SL, Freire-de-Lima CG, Rocco PR, Neves JS, et al. Pulmonary antifibrotic mechanisms aspirin-triggered lipoxin A(4) synthetic analog. Am J Respir Cell Mol Biol 2013;49:1029-37. https://doi.org/10.1165/rcmb.2012-0462OC
Cited by
- Recent Advances in Predicting Mortality and Progression of Systemic Sclerosis-Associated Interstitial Lung Disease vol.83, pp.4, 2020, https://doi.org/10.4046/trd.2020.0100